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330corticosteroids and implantable
cardiac deﬁbrillators (ICD) have
considerable side effects. Our
objective was to identify how
ﬁndings on cardiac PET imaging
related to adverse cardiac events in
patients referred for evaluation
of known or suspected cardiac
sarcoidosis.Methods
Study population. We studied
consecutive patients without coro-
nary artery disease referred for
an initial cardiac PET examination
at Brigham andWomen’sHospital
(Boston, Massachusetts) for theCardiac PET/CT Perfusion and Metabolism
ategory 1), abnormal perfusion or metabolism (Categevaluation of known or suspected cardiac sarcoidosis between
May 2006 and January 2011. The study was approved by the
Partners Healthcare Institutional Review Board and con-
ducted in accordance with institutional guidelines.
PET imaging procedure and analysis. Patients underwent
resting myocardial perfusion and metabolic imaging using
rubidium-82 and 18F-labeled ﬂuorodeoxyglucose (FDG)
and a whole-body PET-CT scanner. Images were inde-
pendently interpreted by 2 experienced cardiologists and
were divided into one of the following patterns: normal
perfusion and metabolism, abnormal perfusion or metabo-
lism, or abnormal perfusion and metabolism (Fig. 1).
Normal metabolism was deﬁned as either complete sup-
pression of FDG from the myocardium or diffuse FDG
uptake without any areas of focal uptake. In addition, for
each patient, the presence or absence of focal right ventric-
ular (RV) FDG uptake was recorded (Fig. 2). Whole-body
FDG images were interpreted by readers who were blindedImaging
ory 2), abnormal perfusion and metabolism (Category 3). FDG ¼ ﬂuorodeoxyglucose.
Figure 2 Examples of Focal Inﬂammation Involving Right Ventricle
Example 1: 50-year-old female who had pacemaker implantation for heart block after presenting with episodes of lightheadedness. PET/CT obtained for suspected cardiac
sarcoidosis identiﬁed a medium sized perfusion defect throughout the basal septum with increased FDG uptake (“mismatch pattern”). There was also FDG uptake involving
the apex and RV free wall (arrow). Whole-body images show FDG uptake in the liver and spleen and in paratracheal lymph nodes. EMBx identiﬁed the presence of
granulomas consistent with the diagnosis of sarcoidosis. Interrogation of her ICD 3 months later identiﬁed the presence of rapid VT at a rate of 200 beats/min, which
required antitachycardia pacing therapy. Example 2: 48-year-old male with pulmonary sarcoidosis who was referred for PET/CT for suspected cardiac involvement. He was
found to have a perfusion defect associated with focal FDG uptake along the basal anterior and inferior septum as well as multiple focal areas of FDG uptake throughout
the right ventricle (arrows). Lymph node biopsy results conﬁrmed the presence of sarcoidosis. Less than 1 month after ICD implantation, he had an episode of VT
(see rhythm strip). CT ¼ computed tomography; PET ¼ positron emission tomography; other abbreviations as in Figure 1.
JACC Vol. 63, No. 4, 2014 Blankstein et al.
February 4, 2014:329–36 Use of Positron Emission Tomography in Cardiac Sarcoidosis
331to the cardiac PET results to assess for any active extra-
cardiac disease (Online Fig. 1, Online Table).
Ascertainment of clinical data. Medical history, including
risk factors and medication use, was ascertained at the time
of the study by patient interviews as well as by reviews of
electronic medical records. We used the revised guidelines
for the diagnosis of cardiac sarcoidosis from the JMHW (6)
in order to classify patients as JMHW-positive (þ) or
JMHW-negative () (Online Fig. 2).
Ascertainment of outcomes. The primary outcome was
death from any cause or documented sustained VT. Patients’
vital status was ascertained from the Social Security Death
Index (SSDI). For patients with ICDs, device interrogation
records were used to identify any ventricular arrhythmias
requiring cardioversion or antitachycardia pacing. Outcomes
were also ascertained by comprehensive review of electronicmedical records, mailed patient questionnaires, and scripted
phone interviews. All signiﬁcant patient self-reported events
were veriﬁed using medical records. Follow-up was available
for 121 of the 125 (97%) patients. Of the 4 patients who
were lost to follow-up, 2 refused to participate, 2 could not
be contacted, and all were alive per SSDI data. As
a secondary outcome, we also assessed the endpoint of
cardiac death or sustained VT. Cardiac death included any
death attributed to heart failure and/or cardiac arrhythmias.Results
Baseline patient characteristics are listed in Table 1.
Patient outcomes. Over a median follow-up of 1.5 years,
31 patients (26%) experienced death or VT. There were 27
(23%) VT events requiring device related therapies (n ¼ 25)
Table 1
Baseline Characteristics Stratiﬁed by Presence or Absence of
Subsequent Adverse Events
Characteristic
All Patients
(N ¼ 118)
Patients With
Adverse Events
(n ¼ 31)
Patients Without
Adverse Events
(n ¼ 87) p Value
Age (yrs) 51.5  11.2 50.3  9.5 51.9  11.7 0.52
Males 67 (57%) 22 (71%) 45 (52%) 0.06
Race
White 91 (77%) 23 (74%) 68 (78%) 0.07
Black 19 (16%) 8 (26%) 11 (13%)
Other/unknown 8 (7%) 0 (0%) 8 (9%)
Reason for testing
Known cardiac sarcoidosis (prior to PET) 9 (8%) 3 (10%) 6 (7%) 0.36
Known extracardiac sarcoidosis with no known
cardiac involvement (prior to PET)
21 (18%) 4 (13%) 17 (20%) 0.38
Evaluation of cardiac signs and symptoms
Syncope 20 (17%) 4 (13%) 16 (18%) 0.48
Heart failure 17 (14%) 3 (10%) 14 (16%) 0.38
Palpitations 7 (6%) 1 (3%) 6 (7%) 0.45
Ventricular tachycardia 24 (21%) 9 (31%) 15 (18%) 0.13
Electrocardiographic data (available for
120 patients)
Right bundle branch block 21 (19%) 4 (14%) 17 (20%) 0.44
Left bundle branch block 7 (6%) 1 (3%) 6 (7%) 0.48
Left axis deviation 22 (19%) 6 (21%) 16 (19%) 0.85
AV block 44 (39%) 13 (45%) 31 (37%) 0.45
Premature ventricular contractions 12 (11%) 4 (14%) 8 (10%) 0.52
Ventricular function (by gated PET)
Ejection fraction (%) 47  16 40  15 49  16 0.007
End-diastolic volume (ml) 154  90 173  112 147  80 0.15
End-systolic volume (ml) 91  79 115  100 82  69 0.05
Baseline medications and devices
Steroid treatment at baseline 31 (26%) 11 (35%) 20 (23%) 0.18
ICD (at baseline or upon follow-up) 64 (54%) 28 (90%) 36 (41%) <0.001
Implanted prior to PET 48 24 24
Implanted after PET 16 4 12
JMHW criteria (of 112) 0.03
Negative 80 (66%) 15 (50%) 59 (72%)
Positive 38 (34%) 15 (50%) 23 (28%)
Histological diagnosis: (þ) EM biopsy results 13 9 4 0.001
Clinical diagnosis: all with tissue or clinical
diagnosis of extra cardiac disease,
ECG abnormality AND 1 or more
of the following:
25 6 19 0.50
Abnormal wall motion 17 5 12
Abnormal wall thinning/thickening 16 4 12
Abnormal left ventricular dilatation 15 4 11
Abnormal intra-cardiac pressure 1 0 1
Continued on the next page
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332or emergency room admission (n ¼ 2). There were 8 (7%)
deaths, including 4 patients who also had a VT event.
Compared to patients without events, those with events
were more likely to have a lower left ventricular ejection
fraction (LVEF) and to meet JMHW criteria (Table 1).
PET ﬁndings. Forty-seven patients (40%) had normal
cardiac PET ﬁndings (32 had complete suppression of FDG,
15 had diffuse uptakewith no areas of focal increase), 37 (31%)
hadmyocardial perfusion defects or focal FDGuptake, and 34
(29%) had abnormalmyocardial perfusion and FDG imaging.The corresponding annualized event rate for these three
groups were 7.3%, 18.4%, and 31.9%, respectively (p< 0.01).
Six of the 47 patients (13%) with normal cardiac PET
results experienced an adverse event (4 VT events and 3
deaths, 1 in a patient who also had VT). Of note, all 6 of
these patients had cardiomyopathy, 5 had LV systolic
dysfunction and 1 had severe RV systolic dysfunction from
pulmonary hypertension. None of these 6 patients had extra-
cardiac FDG uptake (see the Online Table). Patients with
complete suppression of myocardial FDG uptake tended to
Table 1 Continued
Characteristic
All Patients
(N ¼ 118)
Patients With
Adverse Events
(n ¼ 31)
Patients Without
Adverse Events
(n ¼ 87) p Value
Positive biopsy results at any time
(may be >1 site)
28 (24%) 5 (16%) 23 (26%) 0.25
Lung 6 0 6
Lymph node 17 5 12
Skin 3 0 3
Eye 1 0 1
Bone 1 0 1
Cardiac MRI results (available for 39 patients) 0.30
No late enhancement 13 2 11
(þ) LGE of myocardium 26 8 18
Cardiac PET results
Abnormal perfusion OR metabolism 37 (31%) 11 (35%) 26 (30%) 0.56
Abnormal perfusion AND metabolism 34 (28%) 14 (45%) 20 (23%) 0.019
Right ventricular uptake of FDG 11 (9%) 8 (26%) 3 (3%) <0.001
Lateral wall uptake of FDG only 5 (4%) 0 (0%) 5 (6%) 0.17
Values are mean  SD or n (%).
AV ¼ atrioventricular; ECG ¼ electrocardiogram; EM ¼ endomyocardial; FDG ¼ ﬂuorodeoxyglucose; ICD ¼ implantable cardiac deﬁbrillator;
JMHW ¼ Japanese Ministry of Health and Welfare; LGE ¼ late gadolinium enhancement; MRI ¼ magnetic resonance imaging; PET ¼ positron
emission tomography.
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333have a lower event rate than those with diffuse FDG uptake
(6.2% vs. 26.7%, respectively; p ¼ 0.07).
Among the 71 patients with abnormal cardiac PET
results, 11 (15%) had focal RV FDG uptake, of whom 8
(73%) experienced an adverse event, corresponding to an
annualized event rate of 55.2%. All patients who had focal
RV FDG uptake also had abnormal FDG uptake involving
the LV. Six patients with focal RV FDG uptake underwent
endomyocardial biopsy (EMBx), 5 of which had positive
results for sarcoidosis.Table 2 Predictors of Death or Ventricular Tachycardia
Predictor Hazard Ratio (95% CI) p Value
Univariate analysis
Ejection fraction (D10%) 0.77 (0.62–0.95) 0.016
Age (D10 yrs) 0.87 (0.62–1.20) 0.39
Males 1.73 (0.80–3.78) 0.17
History of ventricular tachycardia 1.74 (0.80–3.78) 0.17
Japanese Ministry of Health and Welfare
criteria (þ)
2.33 (1.14–4.78) 0.020
Abnormal perfusion OR metabolism 2.55 (0.94–6.92) 0.065
Abnormal perfusion AND metabolism 3.94 (1.50–10.31) 0.005
Presence of extra-cardiac FDG uptake 0.93 (0.42–2.09) 0.87
Right ventricular uptake of FDG 4.22 (1.87–9.50) 0.001
Multivariable model
Ejection fraction (D10%) 0.78 (0.63–0.98) 0.04
Japanese Ministry of Health and Welfare
criteria (þ)
1.76 (0.83–3.72) 0.14
Abnormal perfusion OR metabolism 2.44 (0.90–6.66) 0.08
Abnormal perfusion AND metabolism 2.87 (1.05–7.85) 0.039
Right ventricular uptake of FDG* 2.82 (1.03–7.60) 0.042
*Added to the model, including left ventricular ejection fraction and diagnosis of cardiac sarcoid-
osis, by the Japanese Ministry of Health and Welfare criteria, but not including abnormal perfusion
and/or metabolism (see the Methods).
CI ¼ conﬁdence interval; FDG ¼ ﬂuorodeoxyglucose.Whole-body FDG PET/CT images demonstrated
abnormal FDG uptake in 31 (26%) patients. There was no
signiﬁcant association between the absence or presence of
extra-cardiac FDG uptake and the cardiac PET examination
results (see Table 3, lower part).
Predictors of death or VT. In univariate analysis, lower
LVEF, positive JMHW criteria, abnormalities in myocardial
perfusion and metabolism, and presence of abnormal FDG
uptake in the RV were all associated with adverse events
(Table 2). The presence of extra-cardiac FDG uptake had
no signiﬁcant association with adverse events.
In multivariable modeling including LVEF, JMHW
criteria, and pattern of abnormality on PET scanning, the
presence of both perfusion and metabolic abnormality on
PET had the strongest association with death or VT
(Table 2, Fig. 3). Similarly, in a multivariable model where
the presence of focal RV FDG uptake was added to LVEF
and JMHW criteria, focal RV uptake remained associated
with subsequent death or VT (Fig. 4). Similar results were
observed when the endpoint of cardiac death or sustained
VT was used (Online Fig. 1).
Discrepancies between cardiac PET ﬁndings and JMHW
criteria. When cardiac PET results were compared with
JMHW criteria (Table 3), modest discordance was observed:
41 individuals with JMHW() criteria had abnormal
PET ﬁndings, of whom 15 had abnormal perfusion and
metabolism (Table 3). Similarly, 11 individuals who were
categorized as having cardiac sarcoidosis by JMHW criteria
had negative PET results. Among the 41 patients who had
abnormal PET but were JMHW(), 11 (27%) had adverse
events, whereas among the 11 patients who were JMHW
positive but had negative PET ﬁndings, there were 2 (18%)
adverse events.
Table 3
Comparison of Findings on Cardiac PET Examination
Versus Clinical Criteria and Extra-Cardiac Findings
Cardiac PET Versus JMHW Criteria
Cardiac PET
(Any Abnormality)
Positive Negative
JMHW criteria Positive 27 11
Negative 41 33
Kappa ¼ 0.13
Cardiac PET
(Abnormal Perfusion
and Metabolism)
Positive Negative
JMHW criteria Positive 16 22
Negative 15 59
Kappa ¼ 0.23
Cardiac PET Versus Extra-Cardiac FDG
Cardiac PET
(Any Abnormality)
Positive Negative
Extra-cardiac
FDG
Positive 19 12
Negative 52 35
Cardiac PET
(Abnormal Perfusion
and Metabolism)
Positive Negative
Extra-cardiac
FDG
Positive 12 19
Negative 22 65
Values are n.
FDG ¼ ﬂuorodeoxyglucose; JMHW ¼ Japanese Ministry of Health and Welfare; PET ¼ positron
emission tomography.
Figure 4
Survival Free of Death or VT Stratiﬁed by
Focal RV Inﬂammation
Survival free of death or VT stratiﬁed by the presence or absence of focal right
ventricular FDG uptake among individuals with abnormal cardiac PET examination
ﬁndings. RV = right ventricular; other abbreviations as in Figure 1 to 3.
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334Comparison of cardiac PET ﬁndings versus
endomyocardial biopsy. Forty-eight patients underwent
RV EMBx as part of their clinical care; 13 (27%) had resultsFigure 3
Survival Free of Death or VT Stratiﬁed by
Cardiac PET Examination Results
Survival free of death or VT stratiﬁed by cardiac PET examination results.
VT ¼ ventricular tachycardia; other abbreviations as in Figures 1 and 2.that were positive for sarcoidosis. When examining EMBx
results by PET examination ﬁndings, we found that 11
patients had negative PET examination and EMBx results
while 1 patient had negative PET and positive EMBx results.
This patient did not experience adverse events during a 3-year
follow-up. Conversely, among the 20 patients with abnormal
perfusion and FDG uptake undergoing EMBx, 9 (45%) were
positive and 11 (55%) were negative. The remaining 3
patients in our cohort with positive EMBx results had focal
FDG uptake without perfusion defects; all experienced
adverse events (2 VT, 1 death) during follow-up.Discussion
Cardiac sarcoidosis is increasingly recognized as a cause
of heart failure and arrhythmias. Both PET and cardiac
magnetic resonance imaging (CMR) imaging have been
proposed as potentially useful tests in the diagnosis of
cardiac sarcoidosis and have been shown to improve diag-
nosis compared to standard diagnostic criteria (3,4,7).
However, there is limited information about the prognostic
implications of imaging ﬁndings, arguably a better measure
of clinical performance. We found that patients who had
abnormalities in both myocardial perfusion and metabolism
(reﬂecting active inﬂammation) had the highest event rate,
particularly if there was also evidence of RV involvement.
Indeed, patients with either a PET mismatch or RV
involvement had a 3-fold increase in the rate of adverse
events. In our cohort, age, JMHW criteria, and presence of
extra-cardiac sarcoidosis were not associated with adverse
events. Our study represents the largest study to date of
patients referred for known or suspected cardiac sarcoidosis
by cardiac PET and is the ﬁrst study to report the prognostic
value of PET ﬁndings. These ﬁndings are potentially
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335important as patients with adverse prognosis may be more
likely to beneﬁt from ICD implantation as well as systemic
anti-inﬂammatory therapies.
A novel insight from our study is that among patients with
abnormal cardiac PET examination ﬁndings, those with focal
RV inﬂammation had a 5-fold higher event rate than those
with normal perfusion and metabolism. Because all these
patients also had PET abnormalities involving the LV, it is
conceivable that the presence of focalRV inﬂammationmay be
a marker for greater extent and/or severity of disease. In
addition, it is also possible that RV involvement signiﬁes active
disease involving a more arrhythmogenic substrate. Involve-
ment of theRVby sarcoidosis is likely under-recognized, and it
is noteworthy that such a ﬁnding has been described as
mimicking arrhythmogenic RV dysplasia (8).
Although not the primary focus of our study, we found
a poor correlation between JMHW criteria and cardiac PET
results. Because JMHWcriteria require histological or clinical
diagnosis of extra-cardiac sarcoidosis, studies in populations
which are known to have disease may have a higher correla-
tion as more patients who meet some of the JMHW criteria
will be categorized as JMHW(þ). The apparently low spec-
iﬁcity of PET examination (versus JMHW criteria) has also
been reported by others (9) and may in part be related to the
limited sensitivity of the JMHW criteria (3).
Our study suggests that inﬂammation-targeted cardiac
PET imaging has a potentially important role in evaluating
patients with known or suspected cardiac sarcoidosis. In
comparison to CMR, PET has the advantage of being able
to image patients with implanted pacemakers or deﬁbrilla-
tors and those with impaired renal function. Furthermore,
the metabolic signal can be used as a marker of disease
activity and to guide the need for and response to immu-
nosuppressive therapies (10). In addition, PET may identify
FDG-avid disease outside the heart, which may be more
accessible to biopsy than the myocardium.
Study limitations. While our study represents a single-
center experience, it is the largest cohort of individuals
with suspected cardiac sarcoidosis undergoing PET reported
to date. As is also true of most previous studies in this ﬁeld,
a limitation of our study is that we were unable to identify
the true diagnostic accuracy of PET, as short of autopsy
ﬁndings, there is no reliable reference standard for cardiac
sarcoidosis. Hence, we used clinical outcomes to deﬁne the
value of imaging ﬁndings. Nonetheless, the outcomes of
death or sustained VT are not unique to cardiac sarcoidosis,
and it is conceivable that patients with both positive and
negative imaging ﬁndings may have had events related to
other cardiomyopathies (e.g., myocarditis). Nevertheless,
such uncertainty is not uncommon in clinical practice, and it
could be argued that regardless of their underlying
pathology, patients at higher risk of arrhythmias or death
should be considered for ICD therapy.
Results of the cardiac PET examinations were available to
clinicians and thus were used to inﬂuence patient care.
Because the initiation of anti-inﬂammatory therapy maylower event rates, we expect that if results were not available,
differences among patient subgroups could potentially be
larger.
While all patients in our study underwent PET imaging,
other tests which might have provided useful diagnostic and
prognostic value, such as Holter monitoring, were not
routinely performed in all patients. The yield of cardiac
biopsy results was low in our study, and image-guided
biopsy, while potentially leading to biopsy results of
higher-risk sites, may result in a higher sensitivity.
The relatively higher event rate observed in our study
might have been the result of referral bias, as our center is
a quaternary care center with frequent referrals of patients
with advanced heart failure and arrhythmias. However,
a similar event rate has been found in other studies. For
instance, Patel et al. (3) found that 8 out of 21 (29%) of
patients with abnormal MRI had death or VT, which is
comparable to our ﬁnding that 25 out of 71 (35%) patients
with abnormal cardiac PET had such events, particularly
when considering that patients referred for PET are more
likely to have higher risk (e.g. patients with existing pace-
maker or deﬁbrillator devices would not be excluded).
Supporting the higher event rate observed in patients treated
with ICD, Schuller et al. (11) reported that appropriate ICD
therapies occurred in 36 (32%) of 112 patients with CS who
underwent ICD implantation and were followed for a mean
of 29 months while Betensky et al. (12) reported ICD
therapies in 17 (38%) of 45 patients with CS followed over
a median of 2 years. However, it should be noted that
appropriate ICD shocks occur more frequently than sudden
cardiac death (13) and that the high event rate noted in our
study and others (11,12) should not be used as a surrogate
for expected mortality. Nevertheless, despite the high event
rate observed in our population and the ﬁnding that even
among patients with normal myocardial perfusion and
metabolism by PET the annual event rate was 7%, we
observed a 4-fold increase in the annual event rate among
30% of patients who had abnormal perfusion and inﬂam-
mation. Thus, while our ﬁndings cannot be used to identify
a true “low risk” group, these results suggest that cardiac
PET can be used to identify individuals who have the
highest risk of adverse events.
Conclusions
The presence of focal perfusion defects and FDG uptake on
cardiac PET identiﬁes patients at higher risk of death or
ventricular tachycardia. These ﬁndings offer prognostic value
beyond Japanese clinical criteria, presence of extra cardiac
sarcoidosis, and LVEF.
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